Axial Biotech, Salt Lake City, Utah, has announced the
commercial launch of a DNA-based test that indicates the likelihood
of progression to a severe curve for children diagnosed with
adolescent idiopathic scoliosis (AIS). It was developed by
utilizing a genome-wide association study that identified a panel
of 53 genetic markers associated with severe curve progression. The
research involved collecting DNA samples from more than 9,500
patients from 85 clinical sites throughout the world. The test was
then further validated in two separate clinical trials. The test
will be marketed under the name “ScoliScoreTM AIS
Prognostic Test.”
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
